Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Lüke J[au]:

The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Matson V et al. Science. (2018)

Targeted agents and immunotherapies: optimizing outcomes in melanoma. Luke JJ et al. Nat Rev Clin Oncol. (2017)

STING pathway agonism as a cancer therapeutic. Flood BA et al. Immunol Rev. (2019)

Search results

Items: 1 to 50 of 327

1.

Toward Improved Environmental Stability of Polymer:Fullerene and Polymer:Nonfullerene Organic Solar Cells: A Common Energetic Origin of Light- and Oxygen-Induced Degradation.

Speller EM, Clarke AJ, Aristidou N, Wyatt MF, Francàs L, Fish G, Cha H, Lee HKH, Luke J, Wadsworth A, Evans AD, McCulloch I, Kim JS, Haque SA, Durrant JR, Dimitrov SD, Tsoi WC, Li Z.

ACS Energy Lett. 2019 Apr 12;4(4):846-852. doi: 10.1021/acsenergylett.9b00109. Epub 2019 Mar 12.

2.

Genomic profiling of metastatic uveal melanoma and clinical results of a Phase I study of the protein kinase C inhibitor AEB071.

Piperno-Neumann S, Larkin J, Carvajal RD, Luke JJ, Schwartz GK, Hodi FS, Sablin MP, Shoushtari AN, Szpakowski S, Roy Chowdhury N, Brannon AR, Ramkumar T, de Koning L, Derti A, Emery C, Yerramilli-Rao P, Kapiteijn E.

Mol Cancer Ther. 2020 Feb 6. pii: molcanther.0098.2019. doi: 10.1158/1535-7163.MCT-19-0098. [Epub ahead of print]

PMID:
32029634
3.

Biology confirmed but biomarkers elusive in melanoma immunotherapy.

Luke JJ, Ascierto PA.

Nat Rev Clin Oncol. 2020 Jan 23. doi: 10.1038/s41571-020-0328-8. [Epub ahead of print] No abstract available.

PMID:
31974501
4.

KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma.

Luke JJ, Ascierto PA, Carlino MS, Gershenwald JE, Grob JJ, Hauschild A, Kirkwood JM, Long GV, Mohr P, Robert C, Ross M, Scolyer RA, Yoon CH, Poklepovic A, Rutkowski P, Anderson JR, Ahsan S, Ibrahim N, M Eggermont AM.

Future Oncol. 2020 Jan;16(3):4429-4438. doi: 10.2217/fon-2019-0666. Epub 2019 Dec 24.

5.

Considering adjuvant therapy for stage II melanoma.

Poklepovic AS, Luke JJ.

Cancer. 2019 Dec 23. doi: 10.1002/cncr.32585. [Epub ahead of print] Review.

PMID:
31869447
6.

BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma.

Labadie BW, Liu P, Bao R, Crist M, Fernandes R, Ferreira L, Graupner S, Poklepovic AS, Duran I, Maleki Vareki S, Balar AV, Luke JJ.

J Transl Med. 2019 Nov 25;17(1):386. doi: 10.1186/s12967-019-02144-7.

7.

Origin of Open-Circuit Voltage Losses in Perovskite Solar Cells Investigated by Surface Photovoltage Measurement.

Daboczi M, Hamilton I, Xu S, Luke J, Limbu S, Lee J, McLachlan MA, Lee K, Durrant JR, Baikie ID, Kim JS.

ACS Appl Mater Interfaces. 2019 Dec 18;11(50):46808-46817. doi: 10.1021/acsami.9b16394. Epub 2019 Dec 3.

PMID:
31738042
8.

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.

Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA.

Cancer Discov. 2020 Jan;10(1):40-53. doi: 10.1158/2159-8290.CD-19-0980. Epub 2019 Nov 15.

9.

Tail state limited photocurrent collection of thick photoactive layers in organic solar cells.

Wu J, Luke J, Lee HKH, Shakya Tuladhar P, Cha H, Jang SY, Tsoi WC, Heeney M, Kang H, Lee K, Kirchartz T, Kim JS, Durrant JR.

Nat Commun. 2019 Nov 14;10(1):5159. doi: 10.1038/s41467-019-12951-7.

10.

Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma.

Trujillo JA, Luke JJ, Zha Y, Segal JP, Ritterhouse LL, Spranger S, Matijevich K, Gajewski TF.

J Immunother Cancer. 2019 Nov 8;7(1):295. doi: 10.1186/s40425-019-0780-0.

11.

Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201).

Luke JJ, Olson DJ, Allred JB, Strand CA, Bao R, Zha Y, Carll T, Labadie BW, Bastos BR, Butler MO, Hogg D, Munster PN, Schwartz GK.

Clin Cancer Res. 2020 Feb 15;26(4):804-811. doi: 10.1158/1078-0432.CCR-19-1223. Epub 2019 Sep 26.

PMID:
31558480
12.

The newest treatments for uveal melanoma.

Luke JJ.

Clin Adv Hematol Oncol. 2019 Sep;17(9):490-493. Review. No abstract available.

PMID:
31549969
13.

Tumor-reprogrammed resident T cells resist radiation to control tumors.

Arina A, Beckett M, Fernandez C, Zheng W, Pitroda S, Chmura SJ, Luke JJ, Forde M, Hou Y, Burnette B, Mauceri H, Lowy I, Sims T, Khodarev N, Fu YX, Weichselbaum RR.

Nat Commun. 2019 Sep 2;10(1):3959. doi: 10.1038/s41467-019-11906-2.

14.

Implementation of a Depth from Light Field Algorithm on FPGA.

Domínguez Conde C, Lüke JP, Rosa González F.

Sensors (Basel). 2019 Aug 15;19(16). pii: E3562. doi: 10.3390/s19163562.

15.

STING pathway agonism as a cancer therapeutic.

Flood BA, Higgs EF, Li S, Luke JJ, Gajewski TF.

Immunol Rev. 2019 Jul;290(1):24-38. doi: 10.1111/imr.12765. Review.

PMID:
31355488
16.

Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy).

Ascierto PA, Agarwala SS, Botti G, Budillon A, Davies MA, Dummer R, Ernstoff M, Ferrone S, Formenti S, Gajewski TF, Garbe C, Hamid O, Lo RS, Luke JJ, Michielin O, Palmieri G, Zitvogel L, Marincola FM, Masucci G, Caracò C, Thurin M, Puzanov I.

J Transl Med. 2019 Jul 22;17(1):234. doi: 10.1186/s12967-019-1979-z.

17.

Clinicopathological challenge: acute blistering and dermal papules in a patient with scleroderma.

Watson W, Vassantachart JM, Luke J.

Int J Dermatol. 2019 Jul 8. doi: 10.1111/ijd.14571. [Epub ahead of print] No abstract available.

PMID:
31286501
18.

Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.

J Immunother Cancer. 2019 Jul 4;7(1):167. doi: 10.1186/s40425-019-0640-y.

19.

A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.

Hong D, Rasco D, Veeder M, Luke JJ, Chandler J, Balmanoukian A, George TJ, Munster P, Berlin JD, Gutierrez M, Mita A, Wakelee H, Samakoglu S, Guan S, Dimery I, Graef T, Borazanci E.

Oncology. 2019;97(2):102-111. doi: 10.1159/000500571. Epub 2019 Jun 21.

20.

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.

J Immunother Cancer. 2019 May 22;7(1):131. doi: 10.1186/s40425-019-0602-4. Review. Erratum in: J Immunother Cancer. 2019 Jul 4;7(1):167.

21.

Approaches to High-Risk Resected Stage II and III Melanoma.

Yushak M, Mehnert J, Luke J, Poklepovic A.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:e207-e211. doi: 10.1200/EDBK_239283. Epub 2019 May 17. Review.

22.

Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma.

Luke JJ.

Oncologist. 2019 Nov;24(11):e1197-e1211. doi: 10.1634/theoncologist.2018-0876. Epub 2019 May 7. Review.

23.

Characterization of Three Novel H3F3A-mutated Giant Cell Tumor Cell Lines and Targeting of Their Wee1 Pathway.

Lübbehüsen C, Lüke J, Seeling C, Mellert K, Marienfeld R, von Baer A, Schultheiss M, Möller P, Barth TFE.

Sci Rep. 2019 Apr 23;9(1):6458. doi: 10.1038/s41598-019-42611-1.

24.

Asystole in Orthognathic Surgery: A Case Report.

Baronos S, Fong W, Saggese NP, Luke J, Ahmed K, Yarmush J.

A A Pract. 2019 Apr 1;12(7):249-251. doi: 10.1213/XAA.0000000000000979.

25.

Modulation of Cav2.3 channels by unconjugated bilirubin (UCB) - Candidate mechanism for UCB-induced neuromodulation and neurotoxicity.

Albanna W, Lüke JN, Schubert GA, Dibué-Adjei M, Kotliar K, Hescheler J, Clusmann H, Steiger HJ, Hänggi D, Kamp MA, Schneider T, Neumaier F.

Mol Cell Neurosci. 2019 Apr;96:35-46. doi: 10.1016/j.mcn.2019.03.003. Epub 2019 Mar 12.

PMID:
30877033
26.

Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study.

Luke JJ, Ghate SR, Kish J, Lee CH, McAllister L, Mehta S, Ndife B, Feinberg BA.

Future Oncol. 2019 Sep 1;15(25):2933-2942. doi: 10.2217/fon-2018-0964. Epub 2019 Feb 25.

27.

Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis.

Johnson DB, Bao R, Ancell KK, Daniels AB, Wallace D, Sosman JA, Luke JJ.

J Natl Compr Canc Netw. 2019 Feb;17(2):114-117. doi: 10.6004/jnccn.2018.7070.

PMID:
30787124
28.

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018).

Berry S, Giraldo N, Nguyen P, Green B, Xu H, Ogurtsova A, Soni A, Succaria F, Wang D, Roberts C, Stein J, Engle E, Pardoll D, Anders R, Cottrell T, Taube JM, Tran B, Voskoboynik M, Kuo J, Bang YL, Chung HC, Ahn MJ, Kim SW, Perera A, Freeman D, Achour I, Faggioni R, Xiao F, Ferte C, Lemech C, Meric-Bernstam F, Werner T, Hodi S, Messersmith W, Lewis N, Talluto C, Dostalek M, Tao A, McWhirter S, Trujillo D, Luke J, Xu C, BoMarelli, Qi J, Qin G, Yu H, Jenkins M, Lo KM, Halle JP, Lan Y, Taylor M, Vogelzang N, Cohn A, Stepan D, Shumaker R, Dutcus C, Guo M, Schmidt E, Rasco D, Brose M, Vogelzang N, Di Simone C, Jain S, Richards D, Encarnacion C, Rasco D, Shumaker R, Dutcus C, Stepan D, Guo M, Schmidt E, Taylor M, Vogelzang N, Encarnacion C, Cohn A, Di Simone C, Rasco D, Richards D, Taylor M, Dutcus C, Stepan D, Shumaker R, Guo M, Schmidt E, Mier J, An J, Yang YY, Lee WH, Yang J, Kim JK, Kim HG, Paek SH, Lee JW, Woo J, Kim JB, Kwon H, Lim W, Paik NS, Kim YK, Moon BI, Janku F, Tan D, Martin-Liberal J, Takahashi S, Geva R, Gucalp A, Chen X, Subramanian K, Mataraza J, Wheler J, Bedard P.

J Immunother Cancer. 2019 Feb 13;7(1):46. doi: 10.1186/s40425-019-0519-y.

29.

The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development.

Olson DJ, Luke JJ.

Immunotherapy. 2019 Feb;11(3):155-159. doi: 10.2217/imt-2018-0171. No abstract available.

PMID:
30730272
30.

A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.

Ott PA, Pavlick AC, Johnson DB, Hart LL, Infante JR, Luke JJ, Lutzky J, Rothschild NE, Spitler LE, Cowey CL, Alizadeh AR, Salama AK, He Y, Hawthorne TR, Bagley RG, Zhang J, Turner CD, Hamid O.

Cancer. 2019 Apr 1;125(7):1113-1123. doi: 10.1002/cncr.31892. Epub 2019 Jan 28.

PMID:
30690710
31.

WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers.

Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF.

Clin Cancer Res. 2019 May 15;25(10):3074-3083. doi: 10.1158/1078-0432.CCR-18-1942. Epub 2019 Jan 11.

PMID:
30635339
32.

Facial Palsy Induced by Checkpoint Blockade: A Single Center Retrospective Study.

Yuen C, Reid P, Zhang Z, Soliven B, Luke JJ, Rezania K.

J Immunother. 2019 Apr;42(3):94-96. doi: 10.1097/CJI.0000000000000254.

PMID:
30614917
33.

Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies.

Frohne CC, Llano EM, Perkovic A, Cohen RD, Luke JJ.

J Immunother Cancer. 2019 Jan 6;7(1):1. doi: 10.1186/s40425-018-0484-x.

34.

The Impact of the Fecal Microbiome on Cancer Immunotherapy.

Osman AEG, Luke JJ.

BioDrugs. 2019 Feb;33(1):1-7. doi: 10.1007/s40259-018-0328-8. Review.

PMID:
30604388
35.

Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.

Labadie BW, Bao R, Luke JJ.

Clin Cancer Res. 2019 Mar 1;25(5):1462-1471. doi: 10.1158/1078-0432.CCR-18-2882. Epub 2018 Oct 30. Review.

PMID:
30377198
36.

Non-invasive evaluation of neurovascular coupling in the murine retina by dynamic retinal vessel analysis.

Albanna W, Kotliar K, Lüke JN, Alpdogan S, Conzen C, Lindauer U, Clusmann H, Hescheler J, Vilser W, Schneider T, Schubert GA.

PLoS One. 2018 Oct 4;13(10):e0204689. doi: 10.1371/journal.pone.0204689. eCollection 2018.

37.

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037).

Mitchell TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Olszanski AJ, Luke JJ, Balmanoukian AS, Schmidt EV, Zhao Y, Gong X, Maleski J, Leopold L, Gajewski TF.

J Clin Oncol. 2018 Sep 28:JCO2018789602. doi: 10.1200/JCO.2018.78.9602. [Epub ahead of print]

38.

Structural basis for activation of SAGA histone acetyltransferase Gcn5 by partner subunit Ada2.

Sun J, Paduch M, Kim SA, Kramer RM, Barrios AF, Lu V, Luke J, Usatyuk S, Kossiakoff AA, Tan S.

Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):10010-10015. doi: 10.1073/pnas.1805343115. Epub 2018 Sep 17.

39.

Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma.

Shah S, Luke JJ, Jacene HA, Chen T, Giobbie-Hurder A, Ibrahim N, Buchbinder EL, McDermott DF, Flaherty KT, Sullivan RJ, Lawrence DP, Ott PA, Hodi FS.

Melanoma Res. 2018 Dec;28(6):605-610. doi: 10.1097/CMR.0000000000000509.

PMID:
30211813
40.

T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection.

Trujillo JA, Sweis RF, Bao R, Luke JJ.

Cancer Immunol Res. 2018 Sep;6(9):990-1000. doi: 10.1158/2326-6066.CIR-18-0277.

41.

[H3F3A mutated multicentric giant cell tumor of bone : A very rare primary bone disease].

Giesche JP, von Baer A, Breining T, Marienfeld R, Mellert K, Lüke J, Schultheiss M, Möller P, Barth TFE.

Pathologe. 2018 Sep;39(5):451-456. doi: 10.1007/s00292-018-0460-8. German.

PMID:
30046846
42.

Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy).

Ascierto PA, Puzanov I, Agarwala SS, Bifulco C, Botti G, Caracò C, Ciliberto G, Davies MA, Dummer R, Ferrone S, Gajewski TF, Garbe C, Luke JJ, Marincola FM, Masucci G, Mehnert JM, Mozzillo N, Palmieri G, Postow MA, Schoenberger SP, Wang E, Thurin M.

J Transl Med. 2018 Jul 21;16(1):207. doi: 10.1186/s12967-018-1568-6.

43.

Reciprocal modulation of Cav 2.3 voltage-gated calcium channels by copper(II) ions and kainic acid.

Neumaier F, Akhtar-Schäfer I, Lüke JN, Dibué-Adjei M, Hescheler J, Schneider T.

J Neurochem. 2018 Nov;147(3):310-322. doi: 10.1111/jnc.14546. Epub 2018 Aug 30.

44.

An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors.

Wang T, Lu R, Kapur P, Jaiswal BS, Hannan R, Zhang Z, Pedrosa I, Luke JJ, Zhang H, Goldstein LD, Yousuf Q, Gu YF, McKenzie T, Joyce A, Kim MS, Wang X, Luo D, Onabolu O, Stevens C, Xie Z, Chen M, Filatenkov A, Torrealba J, Luo X, Guo W, He J, Stawiski E, Modrusan Z, Durinck S, Seshagiri S, Brugarolas J.

Cancer Discov. 2018 Sep;8(9):1142-1155. doi: 10.1158/2159-8290.CD-17-1246. Epub 2018 Jun 8.

45.

Reply to S.C. Formenti et al.

Luke JJ, Chmura SJ.

J Clin Oncol. 2018 Sep 1;36(25):2662-2663. doi: 10.1200/JCO.2018.79.0980. Epub 2018 Jun 5. No abstract available.

PMID:
29870292
46.

The Evolution of Radiation Therapy in Metastatic Breast Cancer: From Local Therapy to Systemic Agent.

Jutzy JMS, Lemons JM, Luke JJ, Chmura SJ.

Int J Breast Cancer. 2018 May 16;2018:4786819. doi: 10.1155/2018/4786819. eCollection 2018. Review.

47.

Review of diagnostic, prognostic, and predictive biomarkers in melanoma.

Ankeny JS, Labadie B, Luke J, Hsueh E, Messina J, Zager JS.

Clin Exp Metastasis. 2018 Aug;35(5-6):487-493. doi: 10.1007/s10585-018-9892-z. Epub 2018 May 2. Review.

PMID:
29722000
48.

Further evidence to support judicious use of antibiotics in patients with cancer.

Luke JJ, Pal SK.

Ann Oncol. 2018 Jun 1;29(6):1349-1351. doi: 10.1093/annonc/mdy153. No abstract available.

49.

Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer.

Sweis RF, Zha Y, Pass L, Heiss B, Chongsuwat T, Luke JJ, Gajewski TF, Szmulewitz R.

J Immunother Cancer. 2018 Apr 4;6(1):24. doi: 10.1186/s40425-018-0334-x.

50.

Photo-stability study of a solution-processed small molecule solar cell system: correlation between molecular conformation and degradation.

Newman MJ, Speller EM, Barbé J, Luke J, Li M, Li Z, Wang ZK, Jain SM, Kim JS, Lee HKH, Tsoi WC.

Sci Technol Adv Mater. 2018 Feb 22;19(1):194-202. doi: 10.1080/14686996.2018.1433948. eCollection 2018.

Supplemental Content

Support Center